Crossmark

Bone Marrow Mesenchymal Stem Cell Extracellular Vesicle Treatment of Respiratory Failure from COVID-19: Endpoint Analysis of Expanded Access Safety Trial

Crossref DOI link: https://doi.org/10.1007/s12015-026-11137-1

Published Online: 2026-05-11

Published Print: 2026-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sengupta, Vikram

Qian, Sascha

Ransom, John T.

Suzuki, Sam

Park, David J.

Melson, Timothy I.

Williams, Brian P.

Walsh, James J.

Awili, Mustafa

Mann, Jack M.

Moseley, Timothy A. https://orcid.org/0000-0003-1352-6610
License Information

Text and Data Mining valid from 2026-05-11

Version of Record valid from 2026-05-11
More Information

Article History

Received: 16 February 2026

Accepted: 20 April 2026

First Online: 11 May 2026

Declarations

:

: The trial protocol was approved by the institutional review board (IRB) at each site (or a centralized IRB as applicable) and overseen by a data and safety monitoring board (DSMB) that was fully independent of both study sponsor and director.

: Written informed consent (or consent by other IRB-approved process) was obtained from each patient, or patient’s legally authorized representative if the patient was unable to provide consent, following a discussion of informed consent principles with the investigator.

: Consent for publication is contained within the informed consent form and permission is granted upon signing the consent form.

: Vikram Sengupta: prior CMO at Direct Biologics, Sascha Qian: prior Associate CMO at Direct Biologics, John T. Ransom: Sr. Medical Writer at Direct Biologics, Timothy A. Moseley: CSO at Direct Biologics.

Document is current

Any future updates will be listed below